William Blair Predicts Increased Earnings for MDxHealth

MDxHealth SA (NASDAQ:MDXH) – Equities researchers at William Blair upped their FY2024 earnings estimates for MDxHealth in a report released on Monday, November 11th. William Blair analyst A. Brackmann now expects that the company will earn ($1.08) per share for the year, up from their previous forecast of ($1.11). The consensus estimate for MDxHealth’s current full-year earnings is ($1.16) per share. William Blair also issued estimates for MDxHealth’s Q4 2024 earnings at ($0.16) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.53) EPS.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings results on Wednesday, August 21st. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.05). The company had revenue of $22.16 million for the quarter, compared to the consensus estimate of $20.66 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%.

A number of other equities research analysts have also commented on MDXH. Piper Sandler lowered their price target on shares of MDxHealth from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Thursday, November 7th. Lake Street Capital started coverage on shares of MDxHealth in a research note on Thursday, October 31st. They set a “buy” rating and a $7.00 price objective for the company.

MDxHealth Stock Performance

NASDAQ:MDXH opened at $1.80 on Thursday. The company has a debt-to-equity ratio of 3.14, a current ratio of 1.54 and a quick ratio of 1.45. MDxHealth has a fifty-two week low of $1.62 and a fifty-two week high of $4.64. The business has a 50 day moving average price of $2.21 and a 200-day moving average price of $2.57.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MDXH. MVM Partners LLC increased its position in shares of MDxHealth by 3.3% during the 3rd quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock valued at $9,706,000 after purchasing an additional 150,000 shares during the last quarter. Perkins Capital Management Inc. increased its holdings in MDxHealth by 70.7% in the 3rd quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock worth $1,555,000 after acquiring an additional 309,500 shares in the last quarter. Finally, OneDigital Investment Advisors LLC raised its stake in MDxHealth by 15.3% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock worth $120,000 after acquiring an additional 7,656 shares during the period.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.